Delving into the Latest Updates on LMT-503 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesDigestive System Disorders

Active Indication

Colitis, UlcerativeCrohn Disease

Inactive Indication-

Originator Organization

Lmito Therapeutics Co. Ltd.

Active Organization

Lmito Therapeutics Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This is a double-blind, randomized, placebo-controlled study, consisting of a single ascending dose (SAD) part with integrated food effect (FE) arm, and a multiple ascending dose (MAD) part to assess the safety, tolerability, and PK of ascending single and multiple oral doses of LMT503. The study will start with the SAD part.

Start Date01 Apr 2025

Sponsor / Collaborator

Lmito Therapeutics Co. Ltd.

NL-OMON51292 / SuspendedNot Applicable

A phase 1, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose and food effect study to evaluate the safety, tolerability, and pharmacokinetics of LMT503 in healthy subjects. - LMT503 First-in-human SAD, MAD, and FE study

Start Date11 Apr 2022

Sponsor / Collaborator

Lmito Therapeutics Co. Ltd.

100 Clinical Results associated with LMT-503

Login to view more data

100 Translational Medicine associated with LMT-503

Login to view more data

100 Patents (Medical) associated with LMT-503

Login to view more data

100 Deals associated with LMT-503

Login to view more data